← All causality assessments
Causality assessment · Causality: well established

Chlorpromazine and Neuroleptic malignant syndrome: is the FAERS signal real?

n=294 co-reports · PRR 74.9 · ROR 78.1
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Causality: well established

Chlorpromazine ↔ Neuroleptic malignant syndrome

n=294 co-reports · PRR 74.9 · ROR 78.1

Chlorpromazine is a first-generation antipsychotic; dopamine D2 blockade in the hypothalamus and basal ganglia underlies neuroleptic malignant syndrome — hyperthermia, rigidity, autonomic instability, and raised creatine kinase — 294 co-reports here (PRR 74.9). NMS is rare but potentially fatal and is why any antipsychotic requires vigilance for the syndrome, with immediate drug withdrawal and supportive care.

Regulatory basis: chlorpromazine prescribing information — neuroleptic malignant syndrome; antipsychotic class warning.

Bradford Hill viewpointStatusNote
Temporality (necessary)partialOnset over days of therapy or dose change
StrengthmetPRR 74.9, very large
ConsistencymetReproduced across antipsychotics
Specificitynot establishedNot specific to any one antipsychotic
Biological gradientmetMore likely with rapid dose escalation
PlausibilitymetCentral dopamine-blockade mechanism
CoherencemetFits the pharmacology
Experimentn/aToo rare for trial detection
AnalogymetAnalogous across the antipsychotic class

This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.

✗ No ClinicalTrials.gov results-posting trial in the top search hits for chlorpromazine captured neuroleptic malignant syndrome as a tracked adverse event in a usable structure. NMS is too rare to appear in the trial populations that studied chlorpromazine, so trials did not capture it as a coded event.